Study Comparing Formulations of Bazedoxifene/Conjugated Estrogens

Phase 1

Completed

• Conditions: Healthy

• Registration Number: NCT00550303
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The primary purpose is to determine bioavailability of Bazedoxifene/conjugated estrogen formulations for future testing purposes.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-10
• Study First Submitted: 2007-10-25
• Study First Submitted QC: 2007-10-25
• Study First Posted: 2007-10-29
• Study Completion: 2007-11
• Status Verified: 2007-12
• Last Update Submitted: 2007-12-18
• Last Update Posted: 2007-12-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 28

Inclusion Criteria

• Healthy, post menopausal women ages 45 to 70

Exclusion Criteria

• Male subjects

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Bioavailability

Secondary Outcome Measures

Name	Time	Method
Safety & tolerability